Literature DB >> 20042502

Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family.

Sumana Chandramouli1, Jeremiah S Joseph, Sophie Daudenarde, Jovylyn Gatchalian, Cromwell Cornillez-Ty, Peter Kuhn.   

Abstract

With an estimated 40% of the world population at risk, dengue poses a significant threat to human health, especially in tropical and subtropical regions. Preventative and curative efforts, such as vaccine development and drug discovery, face additional challenges due to the occurrence of four antigenically distinct serotypes of the causative dengue virus (DEN1 to -4). Complex immune responses resulting from repeat assaults by the different serotypes necessitate simultaneous targeting of all forms of the virus. One of the promising targets for drug development is the highly conserved two-component viral protease NS2B-NS3, which plays an essential role in viral replication by processing the viral precursor polyprotein into functional proteins. In this paper, we report the 2.1-A crystal structure of the DEN1 NS2B hydrophilic core (residues 49 to 95) in complex with the NS3 protease domain (residues 1 to 186) carrying an internal deletion in the N terminus (residues 11 to 20). While the overall folds within the protease core are similar to those of DEN2 and DEN4 proteases, the conformation of the cofactor NS2B is dramatically different from those of other flaviviral apoprotease structures. The differences are especially apparent within its C-terminal region, implicated in substrate binding. The structure reveals for the first time serotype-specific structural elements in the dengue virus family, with the reported alternate conformation resulting from a unique metal-binding site within the DEN1 sequence. We also report the identification of a 10-residue stretch within NS3pro that separates the substrate-binding function from the catalytic turnover rate of the enzyme. Implications for broad-spectrum drug discovery are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042502      PMCID: PMC2826037          DOI: 10.1128/JVI.02044-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Thermofluor-based high-throughput stability optimization of proteins for structural studies.

Authors:  Ulrika B Ericsson; B Martin Hallberg; George T Detitta; Niek Dekker; Pär Nordlund
Journal:  Anal Biochem       Date:  2006-08-10       Impact factor: 3.365

2.  Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Authors:  Wellington Sun; Dennis Cunningham; Steven S Wasserman; Judith Perry; J Robert Putnak; Kenneth H Eckels; David W Vaughn; Stephen J Thomas; Niranjan Kanesa-Thasan; Bruce L Innis; Robert Edelman
Journal:  Hum Vaccin       Date:  2009-01-27

3.  Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.

Authors:  J L Kim; K A Morgenstern; C Lin; T Fox; M D Dwyer; J A Landro; S P Chambers; W Markland; C A Lepre; E T O'Malley; S L Harbeson; C M Rice; M A Murcko; P R Caron; J A Thomson
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

4.  Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro.

Authors:  R Yusof; S Clum; M Wetzel; H M Murthy; R Padmanabhan
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

5.  Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus.

Authors:  Anita E Matusan; Peter G Kelley; Melinda J Pryor; James C Whisstock; Andrew D Davidson; Peter J Wright
Journal:  J Gen Virol       Date:  2001-07       Impact factor: 3.891

6.  Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold.

Authors:  Alexander E Aleshin; Sergey A Shiryaev; Alex Y Strongin; Robert C Liddington
Journal:  Protein Sci       Date:  2007-03-30       Impact factor: 6.725

Review 7.  Attenuated D2 16681-PDK53 vaccine: defining humoral and cell-mediated immunity.

Authors:  J Rabablert; S Yoksan
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 8.  The design of drugs for HIV and HCV.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

9.  HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus.

Authors:  Paul A Johnston; Jennifer Phillips; Tong Ying Shun; Sunita Shinde; John S Lazo; Donna M Huryn; Michael C Myers; Boris I Ratnikov; Jeffrey W Smith; Ying Su; Russell Dahl; Nicholas D P Cosford; Sergey A Shiryaev; Alex Y Strongin
Journal:  Assay Drug Dev Technol       Date:  2007-12       Impact factor: 1.738

10.  Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking.

Authors:  Dariusz Ekonomiuk; Xun-Cheng Su; Kiyoshi Ozawa; Christophe Bodenreider; Siew Pheng Lim; Zheng Yin; Thomas H Keller; David Beer; Viral Patel; Gottfried Otting; Amedeo Caflisch; Danzhi Huang
Journal:  PLoS Negl Trop Dis       Date:  2009-01-13
View more
  26 in total

1.  Structural and functional parameters of the flaviviral protease: a promising antiviral drug target.

Authors:  Sergey A Shiryaev; Alex Y Strongin
Journal:  Future Virol       Date:  2010-09-01       Impact factor: 1.831

2.  Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence.

Authors:  Erika Piccirillo; Benjamin Merget; Christoph A Sotriffer; Antonia T do Amaral
Journal:  J Comput Aided Mol Des       Date:  2016-02-29       Impact factor: 3.686

3.  Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.

Authors:  Lynne Cregar-Hernandez; Guan-Sheng Jiao; Alan T Johnson; Axel T Lehrer; Teri Ann S Wong; Stephen A Margosiak
Journal:  Antivir Chem Chemother       Date:  2011-05-12

Review 4.  Functional interplay among the flavivirus NS3 protease, helicase, and cofactors.

Authors:  Kuohan Li; Wint Wint Phoo; Dahai Luo
Journal:  Virol Sin       Date:  2014-03-26       Impact factor: 4.327

5.  Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives.

Authors:  Kok-Chuan Tiew; Dengfeng Dou; Tadahisa Teramoto; Huiguo Lai; Kevin R Alliston; Gerald H Lushington; R Padmanabhan; William C Groutas
Journal:  Bioorg Med Chem       Date:  2011-12-30       Impact factor: 3.641

6.  Structure-guided fragment-based in silico drug design of dengue protease inhibitors.

Authors:  Tim Knehans; Andreas Schüller; Danny N Doan; Kassoum Nacro; Jeffrey Hill; Peter Güntert; M S Madhusudhan; Tanja Weil; Subhash G Vasudevan
Journal:  J Comput Aided Mol Des       Date:  2011-02-23       Impact factor: 3.686

7.  Ligand-bound structures of the dengue virus protease reveal the active conformation.

Authors:  Christian G Noble; Cheah Chen Seh; Alexander T Chao; Pei Yong Shi
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

8.  Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease.

Authors:  Manolya Ezgimen; Huiguo Lai; Niklaus H Mueller; Kyungae Lee; Gregory Cuny; David A Ostrov; Radhakrishnan Padmanabhan
Journal:  Antiviral Res       Date:  2012-02-11       Impact factor: 5.970

9.  High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.

Authors:  Anuradha Balasubramanian; Mark Manzano; Tadahisa Teramoto; Rajendra Pilankatta; Radhakrishnan Padmanabhan
Journal:  Antiviral Res       Date:  2016-08-15       Impact factor: 5.970

10.  Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro.

Authors:  Huiguo Lai; G Sridhar Prasad; Radhakrishnan Padmanabhan
Journal:  Antiviral Res       Date:  2012-11-02       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.